{"id":3231,"date":"2010-09-20T17:05:46","date_gmt":"2010-09-20T21:05:46","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=3231"},"modified":"2011-07-19T17:45:12","modified_gmt":"2011-07-19T21:45:12","slug":"what-does-gregg-stone-most-want-to-see-at-tct-this-year","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/09\/20\/what-does-gregg-stone-most-want-to-see-at-tct-this-year\/","title":{"rendered":"What Does Gregg Stone Most Want to See at TCT This Year?"},"content":{"rendered":"<p><em>CardioExchange asked Gregg Stone, Director of the <\/em><em>Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting<\/em><em>, what he thinks will be the three most important trials or topics presented at this year&#8217;s conference.<\/em><\/p>\n<p>The most important and impactful trial is undoubtedly the <strong>PARTNER<\/strong> trial, which is a large randomized trial of transcatheter aortic valve implantation compared to medical therapy in patients with inoperable aortic stenosis. If the trial is positive, it will usher into the U.S. a whole new field of transcatheter valve therapies specifically related to aortic valve stenosis. We&#8217;re very excited about that, no matter what it shows, positive or negative. The trial also has worldwide implications, because tens\u00a0of thousands of these procedures have now been performed globally. A large-scale, randomized trial like this trumps everything else.<\/p>\n<p>The second most important trial in my mind is\u00a0<strong>ZILVER PTX<\/strong>, which is the first trial in a long time to test a drug-eluting stent in the peripheral arteries. There&#8217;s been very little in this area and this is a new paclitaxel-eluting stent optimized for the periphery. This trial might also have a big impact on the field, in that it could establish a whole new territory for stents.<\/p>\n<p>My third choice isn&#8217;t one trial, but <strong>a group of trials testing everolimus-eluting stents<\/strong>, which are by far the most popular stents used in the world today. We&#8217;re going to see several very large trials that will either further establish their position or reveal their weaknesses. Two-year results from the SPIRIT IV and COMPARE trials will contain data on nearly 6,000 patients. The everolimus-eluting stents looked great at one year, but how will they look at two years? That&#8217;s a key question. In addition, the comparator in these studies used the relatively weak paclitaxel coating. At TCT this year we&#8217;ll see several trials with a total of 5,500 patients randomized to either everolimus-eluting or the equally potent sirolimus-eluting stents, so it will be much more difficult for the everolimus-eluting stents to demonstrate superiority in these trials.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CardioExchange asked Gregg Stone, Director of the Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting, what he thinks will be the three most important trials or topics presented at this year&#8217;s conference. The most important and impactful trial is undoubtedly the PARTNER trial, which is a large randomized trial of transcatheter aortic valve implantation compared to medical [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[331,398,400,396,401,399,395,397],"class_list":["post-3231","post","type-post","status-publish","format-standard","hentry","category-interventional-cardiology","tag-des","tag-everolimus","tag-paclitaxel","tag-partner","tag-peripheral-stents","tag-sirolimus","tag-tct","tag-transcatheter-valve-therapy"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=3231"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3231\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=3231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=3231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=3231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}